Professor Andrew L. Hopkins elected Fellow of the Royal Society
Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Royal Society, the world’s oldest and most influential scientific society. Andrew is one of the UK’s most eminent science and technology business leaders, pairing pharmaceutical research with the benefits of cutting-edge AI technology to design, discover and develop new precision medicines for people in need.
He joins approximately 1,700 Fellows and Foreign Members of the Royal Society comprising the most distinguished scientists, technology and engineering pioneers from the UK, the Commonwealth and beyond including some 85 Nobel Laureates. Royal Society Fellows and Foreign Members are elected for life in recognition of their exceptional contributions to science.
This prestigious recognition reflects Andrew’s life-long passion for harnessing the power of innovative technologies to deliver high-quality drug candidates and making them accessible to patients. In 2006, he published one of the first papers on large scale machine learning on pharmacology data, in Nature Biotechnology. In 2012 he published, in Nature, one of the first papers to show machine learning and generative algorithms could be used to design novel drug leads to target objectives. In the same year, he founded Exscientia, a pioneer in the use of artificial intelligence to design new drug candidates, leading the team who discovered the first AI-designed drugs to enter human clinical trials.
“Passionate scientists have the power to change the world,” says Andrew Hopkins. “Exceptional science married with outstanding technology can achieve this change even faster and make scientific progress accessible for all. I feel privileged to accept this Fellowship on behalf of the wonderful team at Exscientia – outstanding professionals who collaborate every day with a vision of transforming the lives of millions around the world.”
As CEO of Exscientia, one of the UK’s biggest and fastest growing biotech companies today, Professor Hopkins heads a global team of over 400 scientists and technology experts based in the UK, Austria, US and beyond. For its end-to-end AI-driven precision medicine platform, Exscientia won the Prix Galien USA 2022 for Digital Health, frequently regarded as the equivalent of the Nobel Prize in biopharmaceutical research. Prior to Exscientia, Dr Hopkins held the Chairs of Medicinal Informatics and Translational Biology at the University of Dundee and spent a decade at Pfizer leading informatics groups. He received his doctorate in biophysics from Oxford University and holds a Honorary Chair at the University of Dundee.
Sir Adrian Smith, President of the Royal Society said: “I am delighted to welcome our newest cohort of Fellows. These individuals have pushed forward the boundaries of their respective fields and had a beneficial influence on the world beyond. They are pioneering scientists and innovators from around the world who have confounded expectations and transformed our thinking. This year’s intake have already achieved incredible things, and I have no doubt that they will continue to do so. I look forward to meeting them and following their contributions in the future.”
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.
Exscientia Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to Exscientia’s research and development and product candidates. Any statement describing Exscientia’s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and other factors. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company at the time of this press release. As a result, you are cautioned not to rely on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005177/en/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Quectel Launches Ultra-Compact FCM360W Wi-Fi 6 and Bluetooth 5.1 Module Ideal for Smart Homes and Industrial IoT Use Cases6.6.2023 13:00:00 EEST | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has launched its latest Quectel FCM360W Wi-Fi and Bluetooth module, combining a high-performance processor with Wi-Fi 6 and Bluetooth 5.1 capabilities. With large memory including 512KB SRAM and 4MB of flash memory, the FCM360W is highly versatile, offering a blend of processing power, memory, connectivity and security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005273/en/ Quectel launches ultra-compact FCM360W Wi-Fi 6 and Bluetooth 5.1 module ideal for smart homes and industrial IoT use cases (Photo: Business Wire) The module features standard security features such as WPA-PSK, WPA2-PSK and WPA3-PSK security standards and provides 128-bit AES encryption for added security. The FCM360W supports multiple interfaces including UART, SPI, I2C, I2S, ADC and PWM alongside many low power consumption modes and keep-alive mechanisms, making it ideal for smart home
Kymeta Launches First Flat Panel Antenna for Maritime Industry on OneWeb’s LEO Network6.6.2023 13:00:00 EEST | Press release
World-leading flat panel satellite antenna company Kymeta (www.kymetacorp.com) and low Earth orbit (LEO) satellite communications company OneWeb (oneweb.net) today announced that Kymeta’s electronically steered Peregrine u8 LEO terminal is now commercially available, becoming the first flat panel antenna to serve the maritime market on OneWeb’s LEO network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005230/en/ Kymeta's electronically steered Peregrine u8 LEO terminal. (Photo: Business Wire) This industry-first offering unlocks a new standard of connectivity for maritime customers who require exceptional performance and reliable connectivity at sea where existing networks often don’t reach. Kymeta’s deep roots in the maritime market extend back to the launch of its maritime product line in 2017 and guided the streamlined design of the Peregrine u8 LEO terminal, which is purpose-built for maritime applications. By ta
SmartStream Launches Latest Solution for Onboarding Cash Balances Faster With AI-Enabled Technology6.6.2023 10:53:00 EEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces the latest version of SmartStream Air – with new AI functionality to onboard cash balances faster and more accurately, whilst further improving cash reconciliations. A new development team was set up to research and provide the new functionality in partnership with clients. If cash balances and/or positions are not managed correctly they will eventually lead to errors, financial losses, and even regulatory penalties. The key USP for SmartStream Air version 8 is for quick and easy onboarding of cash balances. The latest solution will continue to leverage its AI-enabled technology and exception management capabilities to provide users with the confidence to manage cash balances instantly. It is a great addition for existing clients, whilst providing a competitive advantage by outperforming slow, expensive, and ineffective systems. Jethro MacDonald, Head of Product Management – AI and Ma
Chatham Hires Jennifer McLellan as a Managing Director in Global ISDA and Regulatory Practice6.6.2023 10:00:00 EEST | Press release
Chatham Financial, a global leader in financial risk management advisory and technology solutions, is pleased to announce Jennifer McLellan is joining the company as a Managing Director in the global OTC derivative instruments, ISDA and regulatory practice. Jennifer established a leading practice in 2011 for law firm Dickson Minto, where she was the Head of Derivatives before joining Chatham. She has advised private equity sponsors, their portfolio investments, UK listed and private corporates, and an array of investment fund boards and managers on the end-user legal and regulatory issues around derivatives. Jennifer brings hands-on knowledge in navigating complicated cross-border M&A leveraged deals, including some of the largest European LBOs. She has advised on all stages of the deal lifecycle including diligence, deal contingent structures, running competitive multi-bank interest rate and FX hedging processes, as well as financial restructuring. On the funds side, Jennifer has a we
Intelsat To Deliver 2Ku Connectivity Upgrade to Japan Airlines6.6.2023 10:00:00 EEST | Press release
Intelsat, operator of the world’s largest integrated satellite and terrestrial network and leading provider of Inflight Connectivity (IFC) services, has reached an agreement with long-time customer Japan Airlines (JAL) to upgrade about 50 Boeing 737s and 767s to the company’s 2Ku inflight connectivity solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005202/en/ Intelsat To Deliver 2Ku Connectivity Upgrade to Japan Airlines (Photo: Business Wire) “We value the trust that JAL has placed in Intelsat throughout our 10-year relationship,” said Dave Bijur, senior vice president of Commercial for Intelsat Commercial Aviation. “JAL was Intelsat’s first non-U.S. commercial aviation customer, and we look forward to continuing to support JAL’s market-leading inflight connectivity service in Japan where their guests enjoy free service.” In addition to the fleet of Boeing 737s and 767s, JAL’s subsidiary airline, J-AIR Co. Lt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom